Medtronic announced a series of regulatory and clinical milestones aimed at expanding the capabilities and market reach of its Hugo™ robotic-assisted surgery (RAS) system in the United States. The company submitted 510(k) applications seeking FDA clearance for the use of Hugo in general surgery, including hernia repair, and gynecologic procedures, potentially opening the platform to some of the highest-volume surgical specialties.

The company also filed a 510(k) submission for the LigaSure™ RAS Maryland instrument, which would bring Medtronic’s widely adopted vessel-sealing technology to the Hugo platform. LigaSure has been used in more than 35 million procedures globally and is expected to enhance surgeon precision and efficiency during robotic-assisted operations.

In addition, Medtronic received FDA clearance for ProGrip™ Advanced, a next-generation self-gripping mesh designed for robotic-assisted ventral hernia repair. The product is intended to improve handling and deployment during minimally invasive procedures, supporting a growing shift toward robotic surgery and outpatient care settings.

Further strengthening its regulatory pathway, Medtronic completed patient enrollment in its Embrace Gynecology clinical study, a key step toward securing U.S. approval for gynecologic procedures on the Hugo platform. Together, these developments expand Medtronic’s surgical ecosystem and reinforce its strategy to compete in the rapidly growing robotic surgery market, according to the company.